Five new practices clinicians should avoid in rheumatology by American Academy of Pediatrics
The American Academy of Pediatrics has expanded its Choosing Wisely campaign with 5 new practices clinicians should avoid in rheumatology. Fellow members of the American Academy of Pediatrics Section on Rheumatology were polled to create a list of practices that “resulted in misuse of laboratory studies and resources.” The list was broken down into 5 statements addressing the most common misconceptions when encountering pediatric autoimmune conditions.
Five Things Physicians and Patients Should Question Rheumatology-
1. Do not prescribe opioids for chronic pain management in patients with autoimmune disease.
Opioids are generally acceptable in pediatric medicine for short-term pain control associated with surgery or trauma. They are not recommended for the treatment of chronic pain. Research has shown morphine and similar medications are not superior to ibuprofen and have significantly more adverse effects, e.g. opioid dependence and withdrawal symptoms. Adverse effects may occur after as few as 5 days of use. Use of opioids for medical purposes in adolescence also increases the risk of long-term use and misuse in adulthood. Opioids do not reduce inflammation from active arthritis and should be reserved for short-term use in cases of severe pain secondary to joint damage. Long-term pain control should be addressed with a multidisciplinary approach combining pharmacologic, behavioural, and exercise-based modalities.
2. Do not order antinuclear antibody (ANA) and another autoantibody testing on a child unless there is strong suspicion or specific signs of autoimmune disease.
The antinuclear antibody (ANA) has a high sensitivity for only one disease, systemic lupus erythematosus (SLE), but has very poor specificity for SLE and every other rheumatic disease. Therefore, it is not useful or indicated as a general screen of autoimmunity.
A positive ANA may occur secondary to polyclonal activation of the immune system following an infection, or it may be positive without any identifiable reason/disease in up to 32% of the population. Limiting patients on which to order ANA would reduce unnecessary physician visits and laboratory expenses as well as parental anxiety. “Lupus panels” and other similar panels should also not be ordered without concerns for specific autoimmune disease. Additionally, since the ANA may always be positive and may fluctuate in titer, it is not recommended to retest it unless there is some new clinical concern.
3. Do not test for Lyme disease as a cause of musculoskeletal symptoms without an exposure history or appropriate exam findings.
The musculoskeletal manifestations of Lyme disease include brief attacks of arthralgia with early disseminated Lyme and/or intermittent or persistent episodes of arthritis in one or a few large joints, with a predilection for the knee, in late disease. Lyme testing in the absence of these features and without appropriate exposure from living in or traveling to a Lyme endemic area increases the likelihood of false-positive results and may lead to unnecessary follow-up and therapy. Diffuse arthralgias, myalgias, or fibromyalgia alone are not criteria for musculoskeletal Lyme disease.
4. Do not send periodic fever syndrome genetic panels prior to infectious and oncologic work up or in a patient without clear evidence of recurrent fever.
Fever is a common complaint in the pediatric age group with infectious etiology as the most common followed by malignancy. Thorough history and physical exam in addition to diligent documentation of fever and accompanying symptoms can often help define underlying etiology, minimizing as well as targeting additional work-up. Of note, most children with a periodic fever syndrome do not have a genetic mutation, and the most common periodic fever syndrome – PFAPA (periodic fever, adenitis, pharyngitis, aphthous ulcer) – is not associated with a monogenic mutation.
5. Do not order rheumatoid factor (RF) alone, or as part of a “panel” or “cascade” in children to evaluate for rheumatologic disease such as juvenile idiopathic arthritis (JIA) due to musculoskeletal complaints. Do not let laboratory results guide referral.
Juvenile idiopathic arthritis is a clinical diagnosis, and laboratory studies are used to prognosticate severity. Only 10-30% of children with JIA have a positive RF compared to the majority of adults with rheumatoid arthritis. The relevance of other antibodies such as anti-cyclic citrullinated peptide (anti-CCP) has not been established in the pediatric population. Additionally, RF is nonspecific and can be positive in other diseases, infections, or healthy individuals, and these labs are typically expensive. Patients may still have JIA despite a negative RF, and a positive test with no clinical disease causes significant parental anxiety and may result in additional unnecessary testing.
For more information, visit www.aap.org.